Skip to main content
Premium Trial:

Request an Annual Quote

Natera Sues Progenity, Alleging Noninvasive Prenatal Test Infringes Patents

NEW YORK – Natera has sued Progenity, alleging that the molecular diagnostics firm's noninvasive prenatal Innatal test infringes six of its patents.

The suit comes shortly after Progenity filed for an initial public offering in which it is seeking to raise up to $122.6 million.

In its complaint, filed on Wednesday with the US District Court for the Western District of Texas, Waco Division, Natera claims that the use and sale of Progenity's Innatal Prenatal Screen test infringes six of its patents: US Patents 9,228,234 and 10,522,242, both titled "Methods for noninvasive prenatal ploidy calling"; US Patents 9,424,392, 10,227,652, and 10,240,202, all titled "System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals;" and US Patent 10,266,893, titled "System and method for cleaning noisy genetic data and determining chromosome copy number."

Natera is seeking injunctive relief, monetary damages, court expenses, and a jury trial.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.